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Abstract: Introduction: Preeclampsia is a specific gestational syndrome that reduces organ perfusion due to vascular
spasm and endothelial activation. Despite the use of magnesium sulfate, the patient’s blood pressure some-
times remains uncontrolled, and therefore, it is necessary to use other medications, especially diuretics and
Methyldopa. Hence, the aim of this study was to compare Lasix and Methyldopa in controlling postpartum hy-
pertension in preeclampsia patients after magnesium sulfate treatment. Methods: This double-blind random-
ized clinical trial was carried out on 100 women with preeclampsia referred to Akbar Abadi Hospital-Iran. In the
first 24 hours after the termination of pregnancy, the participants’ blood pressure was measured and those with a
blood pressure of 140/90 to 160/100 were divided into two groups. In the first and second 24 hours, and then one
week after the intervention, systolic and diastolic blood pressure as well as diuresis and drug complications in
the two groups were assessed and compared. The present study was registered in the Iranian Registry of Clinical
Trials (IRCT) under the ID of IRCT20180114038349N1. Results: The mean age of individuals was 29.93 ± 6.65 in
the Methyldopa group, and 32.35 ± 4.85 in the Lasix group (P = 0.479). Systolic and diastolic blood pressure had
a substantial reduction in both groups, but there was no significant difference between the two groups (P> 0.05).
Systolic blood pressure was reduced by 31 mmHg (reduction from 146 to 115) in the methyldopa group and 30
mmHg (reduction from 145 to 114) in the Lasix group. Furthermore, the reduction in diastolic blood pressure
was 25 mmHg (from 95 to 70) in the methyldopa group, and 21 mmHg in the Lasix one (from 91 to 70). Con-
clusion: The present study showed that using Lasix and methyldopa was effective enough in changing blood
pressure in patients with preeclampsia, and the effects observed in the two groups were the same. Therefore, it
could have a great impact on the wellbeing of couples.
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1. Introduction
Blood pressure disorders, bleeding, and infections, account
for maternal mortality in developing countries, and cause a
majority of complications and deaths associated with preg-
nancy (1). Blood pressure disorders are among the most
common abnormalities that occur during pregnancy (1-3).
Preeclampsia is a specific pregnancy syndrome character-
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ized by high blood pressure and proteinuria (4, 5).
The incidence rate of preeclampsia is about 5%. In saying
that, a significant variation of this disorder has been reported
(6-8). Some of its serious complications are end-organ in-
volvement including heart failure, pulmonary edema, in-
volvement of liver and coagulation system, and ultimately
HELLP syndrome (Hemolysis Elevation of Liver Enzyme Low
Tumble)(9). There is also the possibility of brain involvement
and seizure, and even maternal death. On another note, due
to the problems with uterine placental bloodstream, IUGR
(Intrauterine Growth Retardation) and IUFD (Intrauterine
Fetal Death) may occur, too (10, 11).
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Regarding the great importance of preeclampsia and its risks
of maternal and infant complications and mortality, pro-
viding methods to reduce hypertension during pregnancy is
very important. The use of antihypertensive, to increase the
length of pregnancy or reduce prenatal outcomes in pregnant
women with different types and severity of hypertension, has
been highly considered by physicians and researchers. De-
spite decades of extensive research, the onset or exacerba-
tion of gestational hypertension is unknown, and hyperten-
sive disorders are still among the most important unresolved
issues in obstetric medicine and midwifery (12). In general,
preeclampsia is a specific gestational syndrome in which or-
gan perfusion is reduced due to vascular spasm and activa-
tion of endothelium (13, 14). Therefore, treatments such as
magnesium sulfate mainly focus on this issue and affect va-
sodilatation (15-17).
In preeclampsia trend, a reduction in urine volume is usu-
ally indicative of the worsening of the disease, and sponta-
neous diuresis translates into improved conditions. Thus, in
the treatment of preeclampsia, the development of diuresis is
considered a therapeutic goal (18, 19). For example, in choos-
ing a crystalloid solution suitable for preeclampsia patients,
ringer is preferred to normal saline, due to causing faster di-
uresis.
Today, there is a consensus around the world over the use of
magnesium sulfate as a selective treatment for preeclamp-
sia and eclampsia. The drug is used at a dose of 2-4 grams
of acetate and 1-5 grams per hour by injection in a solution
until 24 hours after lowering blood pressure. But its benefi-
cial mechanism is ambiguous. Although high-concentration
magnesium ion has a direct effect on smooth muscle relax-
ation, the magnesium that affects preeclampsia does not sig-
nificantly reduce systemic blood pressure (1, 20, 21). There-
fore, it is necessary to use other medications, especially di-
uretics and methyldopa. Diuretics are used in different types
of high blood pressure. In order for methyldopa to work more
effectively and to reduce fluid retention, a diuretic is usually
prescribed. Therefore, the aim of this study was to compare
Lasix with methyldopa in controlling postpartum hyperten-
sion in preeclampsia patients after magnesium sulfate treat-
ment. To the best of our knowledge, this is the first study
comparing the effects of Lasix with methyldopa in control-
ling postpartum hypertension in preeclampsia patients.
2. Material and Methods
This study was a double-blind randomized clinical trial car-
ried out on women with preeclampsia who referred to Shahid
Akbar Abadi Hospital in Tehran, Iran. The study was ap-
proved by the Ethics Committee of Iran University of Medical
Sciences, Tehran, Iran. It was then registered in the Iranian
Registry of Clinical Trials website (IRCT) and received a clini-
cal trial code number IRCT20180114038349N1. An informed
consent was obtained from all participants in the study, after
examining the inclusion and exclusion criteria. The women
with preeclampsia who had received magnesium sulfate in
the first 24 hours after the termination of pregnancy and
were admitted to the ICU with a blood pressure of 140/90 to
160/100, were included in the study. While pregnant women
with complicated pregnancies, such as GDM, heart diseases,
kidney diseases, sensitivity to Lasix and methyldopa, and
major adverse drug complications, were excluded.
After examining the inclusion and exclusion criteria, women
were randomly assigned to the control and intervention
groups with an allocation ratio of 1:1 in blocks of four and
six. Opaque sealed envelopes numbered sequentially with
the group type written in them were used for allocation con-
cealment. The envelopes were prepared by a researcher not
involved in data collection. The envelopes were opened af-
ter completing the pre-intervention questionnaires. There-
fore, before random assignment of participants, researcher
and participants were unaware of what participants were as-
signed to each group (Allocation Concealment). The first
group received 20 mg oral tablet of Lasix twice a day, and
the second group received 250 mg oral tablet of methyldopa
3 times a day. The primary outcome in this study was sys-
tolic and diastolic blood pressure measured at the beginning
of the study and 6 hours, 48 hours, and one week, after the
intervention. Another outcome studied was diuresis, which
was measured in both groups in the first and second 24 hours
after the intervention. The sample size in this study was cal-
culated to be 50 people in each group by taking into account
the results of previous studies with the mean and standard
deviation of 131 ± 13 and 138± 13, 80% power and Îś = 0.05.
2.1. Statistical Data Analysis
The results were presented as mean and standard deviation
(mean ± SD) for quantitative variables, and as numbers and
percentages for those of qualitative categorical nature. To
compare quantitative and qualitative variables, the t-test and
the chi-square test were used, respectively. The independent
t-test was also used to determine the changes in the indi-
cators in both intervention and control groups. The signifi-
cance level was considered lower than 0.05. The SPSS 24 soft-
ware was used to analyze the data.
3. Results
The average women’s age was 29.93 ± 6.65 in the Methyldopa
group, and 32.35 ± 4.85 in the Lasix group (P = 0.479). Be-
sides, the mean BMI and children’s weight in the Methyldopa
group were 28.95 ± 4.82 and 2444.58 ± 744.59, respectively,
while they were 27.84 ± 4.13 and 2721.0±887.59 in the Lasix
group. The differences were not statistically significant (P =
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Table 1: Comparison of baseline data in the two groups
Variables Methyldopa group(n=50) Lasix group(n=50) P-Value
Age 29.93 ± 6.65 32.35 ± 4.85 0.479
BMI 28.95 ± 4.82 27.84 ± 4.13 0.277
Infant Wieght 2444.58 ± 744.59 2721.0 ± 887.59 0.668
Table 2: Comparison of systolic blood pressure in both groups at baseline and 6 hours, 46 hours, and 1 week after intervention
Variables Time Methyldopa group(n=50) Lasix group(n=50) P -Value
Base line 146.66 ± 7.78 145.55 ± 7.26
Systolic Blood After 6 hours 129.16 ± 12.40 132.22 ± 12.01 0.922
Pressure After 48 hours 119.58 ± 12.87 119.44 ± 6.34
After 1 week 115.00 ± 5.22 114.44 ± 5.27
0.277) (P = 0.669) (Table 1).
Comparison of the systolic blood pressure in both groups
showed that there was a significant decrease in the systolic
blood pressure at different times in both groups, but this dif-
ference was not statistically significant (F = 0.010, P = 0.922).
However, it could be said that the systolic blood pressure
was reduced by 31 mmHg (reduction from 146 to 115) in the
methyldopa group and 30 mmHg (reduction from 145 to 114)
in the Lasix group (Table 2).
Also, there was a major reduction in blood pressure at dif-
ferent times in both groups, but there was no significant dif-
ference between the two groups in terms of diastolic blood
pressure (F = 0.005, P = 0.974). The reduction was 25 mmHg
(from 95 to 70) in the methyldopa group, and 21 mmHg in the
Lasix one (from 91 to 70) (Table 3).
In both groups, there was a noteworthy decrease in
hemoglobin count in the first and the second 24 hours com-
pared to the baseline, but the difference was not statistically
significant (F = 0.593, P = 0.448) (Table 4). Furthermore, di-
uresis increased in both groups within the second 24 hours
compared to the first one after the intervention, but the dif-
ference was not significant (P = 0.541) (Table 4). Moreover,
no side effects related to the medication were seen in either
intervention groups
4. Discussion
Postpartum blood pressure is a common phenomenon and
is often a cause of concern. After giving birth to a child, in-
creased intravascular hydrostatic pressure, increased capil-
lary permeability, and low vascular oncotic pressure may oc-
cur. As a result of this fluid mobilization process, the central
pressure and the overall pulmonary-capillary pressure are in-
creased. This may cause pulmonary edema. Therefore, di-
uretics may be a preferable option for the treatment of hyper-
tension in such situations20. In the present study, the com-
parison of systolic and diastolic blood pressure in the two
groups showed a significant decrease in both blood pressure
types at different times, but this difference was not statisti-
cally significant. There was a decrease in blood pressure in
both groups, but this decrease was higher in the Methyldopa
group.
In terms of decreased blood pressure, the results of this
study were consistent with those of the study conducted
by Ascarelli et al. In their study, Ascarelli et al. showed
that postpartum systolic blood pressure was reduced signifi-
cantly within 2 days after delivery only in patients with severe
preeclampsia who received Lasix (22). In a study to evalu-
ate the effects of Lasix, a total of 108 pregnant women with
severe preeclampsia and over-150 mmHg hypertension were
included within the first 24 hours after delivery. The results
showed that there was no significant difference in the mean
systolic and diastolic as well as the Mean Arterial Pressure
(MAP) between the two groups at admission. One of the rea-
sons why the results of this study were not significant could
be attributed to the small sample size.
The study by Ascarelli et al. had a larger sample size than
that of the present study, and obtained significant results.
Despite the importance of pregnancy-induced hypertension,
few studies have been done on the therapies for postpartum
management of such patients. In a study conducted by FI-
DLER et al. in England (1982), the patients were randomly
divided into two groups to be treated with Timolol or methyl-
dopa (40 patients in each group). The results showed that
treatment of high blood pressure (diastolic blood pressure of
105-95 mm Hg) with methyldopa (750-3000 mg / day) was
not significantly different from treatment with Timolol (15-
60 mg / day) in 80 patients during the study period (9 days),
and had the same effect on the patients’ blood pressure (18,
23). At the end of the study, it was concluded that Timolol
could be an appropriate alternative for methyldopa in the
treatment of high blood pressure 12. A study by Firoz et al.
in 2014 showed that methyldopa could help control gesta-
tional blood pressure in 56% of cases (24). Another result of
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Table 3: Comparison of diastolic blood pressure in both groups at baseline and 6 hours, 46 hours, and 1 week after interventionComparison
of diastolic blood pressure in both groups at baseline and 6 hours, 46 hours, and 1 week after intervention
Variables Time Methyldopa group(n=50) Lasix group(n=50) P-Value
Base line 95.00 ± 7.97 91.50 ± 7.47
Diastolic Blood After 6 hours 78.75 ± 9.07 81.00 ± 11.97 0.947
Pressure After 48 hours 71.25 ± 3.76 73.00 ± 4.83
After 1 week 70.41 ± 1.44 70.50 ± 1.58
Table 4: Comparison of mean hemoglobin in both groups at baseline and 24 and 48 hours after intervention
Variables Time Methyldopa group(n=50) Lasix group(n=50) P -Value
Base line 13.03 ± 1.22 13.00 ± 1.39
Hemoglobin After 24 hours 11.89 ± 1.38 12.31 ± 1.52 0.448
After 48 hours 11.06 ± 1.38 11.71 ± 1.03
Diuresis After 24 hours 1740.02 ± 150.65 1659.90 ± 145.53 0.541
After 48 hours 1967.34 ± 175.34 2011.11 ± 164.42
this study was a significant reduction in hemoglobin count
in the first and second 24 hours compared with the baseline
in both groups, but this difference was not statistically signif-
icant. The results also showed a significant decrease in di-
uresis during the second 24 hours after the intervention in
both groups, compared to the first 24 hours which was not
statistically significant. In a study by Magee et al. in Canada
(2013), it was suggested that adding some other drugs, in-
cluding nifedipine and methyldopa, did not have much effect
on the treatment of uncontrolled postprandial blood pres-
sure, while Lasix could be somewhat useful for controlling
blood pressure (25).
This is the first study in the world comparing Methyldopa
group with a Lasix one in terms of reducing blood pressure,
and this could be considered a strength of the present study.
On the other hand, measurement of blood pressure at dif-
ferent times would naturally better reflect the effect. In this
study, it was possible to select a larger sample size in the two
groups, and the researchers could also measure more vari-
ables to compare the effects.
5. Conclusion
The present study showed that the use of Lasix and methyl-
dopa had the necessary efficacy to change the blood pres-
sure in preeclampsia patients, although the results were in-
significant. It seems that the effect of this drug in reducing
blood pressure is due to its conversion to Îś-methyl nore-
pinephrine. Central Îś-methyl norepinephrine reduces the
sympathetic flow and thus decreases blood pressure.
In 2005, Ascarelli et al. (22), designed a randomized trial
involving 264 women with preeclampsia at the postpartum
stage. The patients were randomly divided into a group of 20
mg of furosemide per day and a non-treated one. In women
with mild illness, there was a similar situation in terms of
blood pressure control, regardless of receiving treatment or
placebo. However, the patients with severe preeclampsia
who were under treatment, showed a lower mean systolic
blood pressure on the second day, compared to those treated
with placebo.
Studying the need for additional drugs showed that there
was no significant difference in the methyldopa and Lasix
groups in terms of taking additional drugs for controlling
blood pressure. The hemoglobin count measurements in the
first and second 24 hours, showed that there was no signifi-
cant difference between the two groups in terms of reduced
hemoglobin count in the first and second 24 hours. Hence,
it seems that these two drugs are effective for patients with
preeclampsia and have the same benefits. Therefore, it could
have a great impact on the wellbeing of couples. In saying
that, more research with appropriate sample sizes is needed
to further verify this claim.
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tional. 2009;106(45):733.
5. Haghighi L, Nohesara S, Moradi Y, Rashidi M, Moridi
M. Psychological Disorders in Women with Spontaneous
Preterm Delivery. Shiraz E-Medical Journal. 2016;17(10).
6. Lisonkova S, Joseph K. Incidence of preeclampsia: risk
factors and outcomes associated with early-versus late-
onset disease. American journal of obstetrics and gyne-
cology. 2013;209(6):544. e1-. e12.
7. Nordqvist M, Jacobsson B, BrantsÃęter A-L, Myhre R,
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